VolitionRx reports progress in licensing talks with over 12 diagnostic firms and advances in clinical and veterinary assays, including a reimbursement submission for its Nu.Q Lung Cancer test and a feline lymphoma study milestone.
Read More
Tel Aviv University researchers have developed a low-cost blood test that detects lung cancer by analyzing optical DNA fingerprints, achieving 93.1% sensitivity and 90.3% specificity.
Read More
VolitionRx has published peer-reviewed data on its Capture-Seq technology, reporting over 99% pure ctDNA isolation from plasma and 95% detection of early-stage cancers in validation cohorts.
Read More
Cancer Cell Diagnostics has launched the CellSight DNA test, a liquid biopsy that isolates intact circulating tumor cells for genomic profiling from a single blood draw, enabling analysis of over 500 genes and key biomarkers.
Read More
Clinical labs are adopting broader cancer diagnostics—including whole-genome sequencing and multi-omic testing—to deliver more comprehensive molecular insights and improve disease monitoring.
Read More